Please ensure Javascript is enabled for purposes of website accessibility

Why RAPT Therapeutics Stock Is Crushing It Today

By Keith Speights – Jun 14, 2021 at 11:44AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company reported great results from an early-stage study of its experimental atopic dermatitis drug.

What happened

RAPT Therapeutics (RAPT 2.12%) stock was crushing it on Monday, with shares skyrocketing 110.4% as of 11:59 a.m. EDT. The huge gain came after the company announced positive top-line results from a phase 1b clinical study evaluating RPT193 in treating moderate-to-severe atopic dermatitis.

So what

You'd expect that RAPT's results from the early-stage study of RPT193 had to be fantastic for the biotech stock to more than double. And they were.

Patients treated with the company's experimental drug achieved a 36.3% improvement in the Eczema Area and Severity Index (EASI) score from baseline. That was more than twice the 17% improvement seen in patients on a placebo.

The story looked even better with patients experiencing a 50% improvement in EASI score -- 42.9% of patients treated with RPT193 achieved this marked improvement compared to only 10% of patients in the placebo group.

Document with atopic dermatitis printed underneath a Diagnosis heading with several pills and a pen on top of the document.

Image source: Getty Images.

RPT193 also achieved the primary efficacy endpoints on two other measurements: the validated Investigator Global Assessment (vIGA) and pruritis Numerical Rating Scale (NRS). The experimental drug appeared to be well tolerated in the early-stage clinical study, with no serious adverse events reported.

Investors were especially excited about these results because RPT193 is a once-daily oral treatment. If the drug eventually wins regulatory approval, it could have a competitive advantage over rival treatments that are administered via injection.

Now what

RAPT Therapeutics now plans to advance RPT193 to a phase 2b study targeting atopic dermatitis. The company will also evaluate the therapy in a phase 2a study in treating asthma.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

RAPT Therapeutics, Inc. Stock Quote
RAPT Therapeutics, Inc.
RAPT
$23.18 (2.12%) $0.48

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.